Investigation of the immune cell populations in different tissues demonstrated favourable changes in the percentage and number of different T-cell subsets and suppressor cells, leading to improvements in tumour CD8+ T-cell/MDSC and CD8+ T-cell/Treg ratios after the administration of tarloxotinib. The gene discussed is CD8A; the disease is neoplasm.